OpenAccess: Closed

This work is not Open Acccess. We may still have a PDF, if this is the case there will be a green box below.

Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)

Mary O’Brien,Rabab Gaafar,Sanjay Popat,Francesco Grossi,Allan Price,Denis Talbot,Tanja Čufer,Christian H. Ottensmeier,Sarah Danson,Athanasios Pallis,Baktiar Hasan,Jan P. van Meerbeeck,Paul Baas

Mesothelioma

Medicine

Clinical endpoint

2013

Cite this:

Generate Citation

“Phase II study of first-line bortezomib and cisplatin in malignant pleural mesothelioma and prospective validation of progression free survival rate as a primary end-point for mesothelioma clinical trials (European Organisation for Research and Treatment of Cancer 08052)” is a paper by Mary O’Brien Rabab Gaafar Sanjay Popat Francesco Grossi Allan Price Denis Talbot Tanja Čufer Christian H. Ottensmeier Sarah Danson Athanasios Pallis Baktiar Hasan Jan P. van Meerbeeck Paul Baas published in 2013. It has an Open Access status of “closed”. You can read and download a PDF Full Text of this paper here.